(Q37761912)

22 August 2017

1 reference

title

Herpes simplex virus oncolytic vaccine therapy in melanoma (English)

1 reference

22 August 2017

1 reference

Shanthi Sivendran

1

1 reference

22 August 2017

Michael Pan

series ordinal

2

1 reference

22 August 2017

Howard L Kaufman

series ordinal

3

1 reference

22 August 2017

Yvonne Saenger

series ordinal

4

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 July 2010

1 reference

Expert Opinion on Biological Therapy

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

7

1 reference

22 August 2017

page(s)

1145-1153

1 reference

Immunotherapy of melanoma: a critical review of current concepts and future strategies

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

An update on malignant melanoma vaccine research: insights into mechanisms for improving the design and potency of melanoma therapeutic vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Viral vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Chemotherapy and biologic therapies for melanoma: do they work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

BRAF inhibitors: research accelerates in wake of positive findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

ICP34.5 influences herpes simplex virus type 1 maturation and egress from infected cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

The potential for efficacy of the modified (ICP 34.5(-)) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

The herpes simplex virus type 1 U(S)11 protein interacts with protein kinase R in infected cells and requires a 30-amino-acid sequence adjacent to a kinase substrate domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

GM-CSF gene-transduced tumor vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Intralesional injection of herpes simplex virus 1716 in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

A modular analysis framework for blood genomics studies: application to systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2010.495383

10.1517/14712598.2010.495383

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference